|Director, Value Evidence Strategy (Central Nervous System)|
Company: Otsuka Pharmaceuticals
Location: Princeton, NJ
Employment Type: Full Time
Date Posted: 08/18/2021
Expire Date: 10/18/2021
Job Categories: Biotechnology and Pharmaceutical
Director, Value Evidence Strategy (Central Nervous System)|
Reporting to the Senior Director, Value Evidence Strategy, Director, Value Evidence Strategy, will be responsible for leading the strategy development and implementation for HTA for an Otsuka Product. This person will have to lead a cross-functional team, Value Evidence Sub-Committee, to ensure Integrated Value Evidence Plan for a Central Nervous System product and its indications, to have a clear plan for ensuring HTA needs around the world is incorporated and implemented. This person will have to conduct assessment of the HTA landscape in the relevant disease spaces, including conducting HTA consultation and developing clear strategy for value evidence needs for addressing HTA needs.
The Director, Value Evidence Strategy, role is responsible for assessing the value evidence needs for HTA purposes for an Otsuka product and its indications and the development and implementation of the Integrated Value Evidence Plan leading a Value Evidence Sub-Committee for that relevant product and indications globally. This position reports to the Senior Director, Value Evidence Strategy.
The role comprises the following responsibilities
Responsibility for leading and coordinating the health technology and value evidence input into clinical development programs for an Otsuka product.
Serves on product development committee.
Lead Value Evidence Sub-Committee.
Lead the development of Integrated Value Evidence Plan (IVEP) leading a Value Evidence Sub-Committee.
Develops the global value evidence strategy taking into account payer (including health technology assessment agencies), provider, patient, and policy maker evidence needs for an Otsuka product and its indications.
Assess the HTA needs for the assigned product and disease area in general and tracking the methodological needs.
Responsibility for completion of all global deliverables for the assigned product/ indication to support HTA and reimbursement submissions, including economic models, real world evidence, evidence synthesis & meta-analysis, global HTA statistical analysis plan, and global value dossier, and AMCP-format dossier.
Coordinates and provides scientific support for HTA submissions outside the US, with subsidiaries. Leads Company responses to HTA evaluations in the US (e.g., ICER).
Develops and generates post-approval real world evidence on our company's product in collaboration with external researchers and experts in the field.
Responsibility for developing a comprehensive publication and communication plan including presentation and publication of key value evidence at scientific conferences and peer reviewed journals.
PhD in health economics, outcomes research, epidemiology, health services research, health policy, pharmaceutical administration or related field
Minimum 4 years of Pharmaceutical Company or payer experience in the area of access, outcomes research, health economics, Health Technology Assessment or related area.
Experience in pharmaceutical industry with exposure to drug development and international reimbursement/ HTA submissions.